Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYO2
- Development stage
- Preclinical
- Lead developer
- Myocea
- Modality
- Small Molecules
01
Overview
MYO2 is a preclinical small molecule drug candidate developed by Myocea for the treatment of Spinal Muscular Atrophy (SMA). It was identified through Myocea's proprietary screening platform, which utilizes Satellite-like Cells (SLCs) to discover compounds that modulate skeletal muscle and neuromuscular junction (NMJ) biology. MYO2 is designed to target a specific biological pathway referred to as Network 2 to address the muscle-specific components of SMA pathology. This approach aims to provide therapeutic benefit by directly targeting the skeletal muscle and NMJ defects associated with the disease, potentially serving as a complementary therapy to existing SMN-upregulating treatments.
- Other names
- Network 2 SMA small moleculeNetwork2 SMA small moleculeNetwork-2 SMA small molecule
Beyond the preview
Go deeper on MYO2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYO2.